Italfarmaco.es - Research, innovation, productive technology and ... - Italfarmaco

Provided by Alexa ranking, italfarmaco.es has ranked N/A in N/A and 853,826 on the world. italfarmaco.es reaches roughly 3,673 users per day and delivers about 110,188 users each month. The domain italfarmaco.es uses a Commercial suffix and it's server(s) are located in N/A with the IP number 92.205.104.119 and it is a .es domain.

WEBMar 21, 2024 · Research, innovation, productive technology and international expansion. Italfarmaco is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries...

List of domain same IP 92.205.104.119

Keywords on this domain

italfarmaco

Search Results related to italfarmaco.es on Search Engine

Research, innovation, productive technology and ... - Italfarmaco
italfarmaco.com

https://www.italfarmaco.com/en-us/

WEBMar 21, 2024 · Research, innovation, productive technology and international expansion. Italfarmaco is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries...

DA: 30 PA: 6 MOZ Rank: 54

Italfarmaco > The group
italfarmaco.com

https://www.italfarmaco.com/en-us/The-group

WEBItalfarmaco Italia in 2009 and 2010 (with Pletal, Zarelis and Saforelle) markets the largest number of products (Natecal Oro, Fentalgon, Treoject, Natalben più, Inofert). FDA certification renewal for the production plant Italfarmaco. Focus inspection: sterilized pre-filled syringes for Octreotide and Enoxaparina.

DA: 47 PA: 67 MOZ Rank: 59

Italfarmaco > Who we are
italfarmaco.com

https://www.italfarmaco.com/en-us/Who-we-are

WEBWho we are. Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in 1938.

DA: 15 PA: 82 MOZ Rank: 43

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in …
yahoo.com

https://finance.yahoo.com/news/italfarmaco-receives-fda-approval-duvyzat-033900355.html

WEBMILAN, March 22, 2024 -- ( BUSINESS WIRE )-- Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Duvyzat™ (givinostat), a novel histone deacetylase...

DA: 35 PA: 98 MOZ Rank: 54

US FDA approves Italfarmaco's drug for Duchenne muscle …
yahoo.com

https://www.yahoo.com/news/fda-greenlights-italfarmacos-drug-rare-224553179.html

WEBMar 21, 2024 · The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday.

DA: 83 PA: 85 MOZ Rank: 46

Italfarmaco Group Completes FDA Submission of New Drug …
yahoo.com

https://finance.yahoo.com/news/italfarmaco-group-completes-fda-submission-093000641.html

WEBMILAN, June 29, 2023 -- ( BUSINESS WIRE )-- Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug...

DA: 48 PA: 31 MOZ Rank: 20

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of …
yahoo.com

https://finance.yahoo.com/news/results-italfarmaco-pivotal-phase-3-162500974.html

WEBMILAN, March 19, 2024 -- ( BUSINESS WIRE )-- Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6...

DA: 83 PA: 10 MOZ Rank: 29

FDA Approves Italfarmaco's Givinostat for Duchenne Muscular …
neurologylive.com

https://www.neurologylive.com/view/fda-approves-italfarmaco-givinostat-duvyzat-dmd

WEBMar 21, 2024 · Months after an extended review process, the FDA has approved Italfarmaco SpA's givinostat (Duvyzat), a proprietary histone deacetylase (HDAC) inhibitor, as a treatment for patients with Duchenne muscular dystrophy (DMD). 1,2 The treatment is designed to inhibit HDACs, enzymes that prevent gene translation by changing the 3 …

DA: 98 PA: 66 MOZ Rank: 21

Italfarmaco > Organization
italfarmaco.com

https://www.italfarmaco.com/en-us/Organization

WEBA Body of Vigilance. The Italfarmaco Board of Directors approved on 28 May 2010 the Model of Organization of Management and Control complying with the Italian Decree of Law no. 231 and the Code of Ethics. The model represents the business rules of ITALFARMACO S.P.A., which are binding for the Company. This model is intended as …

DA: 83 PA: 67 MOZ Rank: 56

FDA Approves Nonsteroidal Treatment for Duchenne Muscular …
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy

WEBMarch 21, 2024. Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and...

DA: 16 PA: 97 MOZ Rank: 4

Alexa Rank

GLOBAL RANK

853,826

Alexa Reach

0.0001621374

Page length

N/A

Alexa Rank Country N/A

N/A

Daily Unique Visitors

3,673

Monthly Unique Visitors

110,188

Vistor via Country

Country lang

Country code

Total visitor

Country

Country code

Total visitor

United States

23,569

Indonesia

18,434

Taiwan

5,994

United Kingdom

5,322

Brazil

4,815

Nigeria

4,209

Egypt

3,537

Hong Kong

3,339

Canada

3,339

Australia

2,909

Philippines

2,083

India

2,027

Malaysia

1,994

Spain

1,653

Germany

1,609

Mexico

1,543

France

1,454

Italy

1,344

Turkey

1,234

Iraq

1,124

Thailand

1,102

Netherlands

1,058

Israel

1,047

Cambodia

870

Algeria

672

Ireland

606

Romania

584

Jordan

540

Poland

518

Ghana

496

Argentina

474

South Africa

430

Belgium

386

Czechia

353

Ukraine

331

Japan

331

Morocco

320

South Korea

309

Lebanon

298

Saudi Arabia

286

Austria

275

Hungary

264

Sweden

253

Singapore

242

Pakistan

231

Bangladesh

220

Denmark

209

Greece

198

Alexa Traffic Graph

Alexa daily traffic trend graph

Alexa Statistics Graph for italfarmaco.es

Alexa daily pageviews (percent) graph

Alexa Statistics Graph for www.nahklick.de

Alexa daily pageviews per user graph

Alexa time on site (in minutes) graph

Alexa bounce rate (percent) graph

Alexa search visits graph

SEOquake Zone

Title			Tips
Description			Tips
Keywords			Tips
Viewport			Tips
Icon
UTF-8

Mini site formation by Alexa Rank

MOZ Rank

DNS Record

Host	Type	Class	TTL	Extra
italfarmaco.es	HINFO	IN	3600	Cpu: RFC8482 Os:

Hosting and Whois Zone

IP	92.205.104.119
Domain infomation	Conditions of use for the whois service via port 43 for .es domains Access will only be enabled for IP addresses authorised by Red.es. A maximum of one IP address per user/organisation is permitted. Red.es accepts no responsibility whatsoever for the availability of access to WHOIS, which may be suspended at any time and without prior warning at the discretion of the public entity. The service will be limited to the data established by Red.es. The user promises to make use of the service and to carry out any action derived from the aforesaid use in accordance with current applicable regulations, in particular with legislation on “.es” domain names and personal data protection. In particular, the user undertakes not to use the service to carry out abusive or speculative domain name registrations, pursuant to section 5 of the Sixth Additional Provision of Law 34/2002, of 11 July, on Services of the Information Society and Electronic Commerce. Likewise, the User undertakes not to use the service to obtain data, the possession of which may contravene the provisions of Organic Law 15/1999, of 13 December, on Personal Data Protection, and its Regulations, or in Law 34/2002, of 11 July, on Services of the Information Society and Electronic Commerce. Failure to comply with these conditions will result in the immediate withdrawal of the service and any registered domain name which breaches said conditions may be officially cancelled by Red.es. ------------------------------------------------------------------------------------------------------- The IP address used to perform the query is not authorised or has exceeded the established limit for queries.To request access to the service,complete the form located at https://sede.red.gob.es/sede/whois, where you may also consult the service conditions. ------------------------------------------------------------------------------------------------------- More information on each domain may be consulted at www.dominios.es.